Výsledky vyhledávání

P546 Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India

Autor: M K Ranjan, B Kante, S K Vuyyuru, P Kumar, S K Mundhra, R Golla, R Sharma, P Das, P Sahni, G Makharia, S Kedia, V Ahuja

Publikováno v: Journal of Crohn's and Colitis. 16:i493-i494

Background Thiopurines are widely used to maintain remission in both ulcerative colitis (UC) and Crohn’s Disease (CD). Reported effectiveness and tolerability rates have been variable across studies. Moreover, there are only sparse data in the Asia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::98be7148eaf988ceac5ca1aa56819c0e
https://doi.org/10.1093/ecco-jcc/jjab232.673

Zobrazit plný text záznamu

P423 Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries

Autor: M K Ranjan, P Kumar, S K Vuyyuru, B Kante, P Sahu, S Mundhra, R Golla, M Singh, S Virmani, R Sharma, R Panwar, P Das, G Makharia, S Kedia, V Ahuja

Publikováno v: Journal of Crohn's and Colitis. 16:i409-i410

Background Inflammatory bowel disease (IBD) including Ulcerative Colitis (UC) and Crohn’s Disease (CD) is characterized by remitting/relapsing course. A proportion of patients with UC, and almost all patients with CD require long-term immunosuppres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::184b3e7f8a9d102a28de5acbcf354ea5
https://doi.org/10.1093/ecco-jcc/jjab232.550

Zobrazit plný text záznamu

P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease

Autor: M K Ranjan, S K Vuyyuru, B Kante, P Kumar, S K Mundhra, R Golla, R Sharma, P Sahni, P Das, G Makharia, S Kedia, V Ahuja

Publikováno v: Journal of Crohn's and Colitis. 16:i330-i331

Background Withdrawal of thiopurines after remission has been shown to be associated with an increased risk of relapse in patients with inflammatory bowel disease. However, long-term data on thiopurine withdrawal is limited especially from developing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be1dd49746511e28f2ab24e086fa49de
https://doi.org/10.1093/ecco-jcc/jjab232.428

Zobrazit plný text záznamu

P531 Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region

Autor: P Kumar, S K Vuyyuru, B Kante, P Sahu, S Goyal, D Madhu, S Jain, M K Ranjan, S Mundhra, R Golla, M Singh, S Virmani, A Gupta, N Yadav, M Kalaivani, R Sharma, P Das, G Makharia, S Kedia, V Ahuja

Publikováno v: Journal of Crohn's and Colitis. 16:i484-i484

Background Anti-tumour necrosis factor (anti-TNF) therapy use in patients with inflammatory bowel disease (IBD) leads to increased risk of tuberculosis (TB) reactivation despite LTB screening, especially in TB endemic regions. We evaluated the effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20f745f1fc21142a04290c429e236c50
https://doi.org/10.1093/ecco-jcc/jjab232.658

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání